New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
04:55 EDTXLRN, XLRN, XLRN, AGIO, AGIO, AGIO, ALKS, ALKS, ALKS, ALNY, ALNY, ALNY, ARIA, ARIA, ARIA, EPZM, EPZM, EPZM, IMGN, IMGN, IMGN, TSRO, TSRO, TSROLeerink to hold a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 14-16.
News For XLRN;AGIO;ALKS;ALNY;ARIA;EPZM;IMGN;TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
16:51 EDTIMGNImmunoGen files automatic mixed securities shelf
Subscribe for More Information
10:19 EDTARIAOptions with decreasing implied volatility
Subscribe for More Information
August 26, 2015
07:09 EDTALNYVertex, Novavax among select biotechs to buy on weakness, says Piper Jaffray
Subscribe for More Information
August 24, 2015
16:23 EDTEPZMOn The Fly: Top stock stories for Monday
Subscribe for More Information
11:43 EDTALNYThe Medicines Co. and Alnylam Pharmaceuticals hold a joint conference call
Subscribe for More Information
08:11 EDTALKSAlkermes delay for Aristada due to administrative issues, says Jefferies
Jefferies said it appears that the FDA's delay in approving Alkermes' Aristada is due to the agency's need for some additional review time. The firm said the fact that the FDA did not choose to issue a CRL letter gives it confidence that Alkermes should receive full approval in a "few weeks" and it maintains its Buy rating and $76 price target on the stock.
08:02 EDTEPZMEpizyme announces FDA acceptance of IND for tazemetostat
Subscribe for More Information
August 21, 2015
16:01 EDTALKSAlkermes provides update on FDA review of ARISTADA
Alkermes announced that the U.S. FDA has advised Alkermes that it will not be able to complete its review of the New Drug Application for ARISTADA for the treatment of schizophrenia by the Prescription Drug User Fee Act action date of Aug. 22, 2015. The FDA indicated that this delay was expected to be brief, measured in terms of weeks, but could not confirm specific timing. The FDA also indicated that no additional data or information is required from Alkermes at this time. "We are confident in the ARISTADA program and our NDA submission, and we will work closely with the FDA as they complete their review," said Elliot Ehrich, M.D., Chief Medical Officer of Alkermes. "We look forward to bringing ARISTADA to market as a potential new treatment option to help address the significant unmet medical needs of patients living with schizophrenia."
August 20, 2015
07:31 EDTALNYAlnylam Pharmaceuticals to hold a roundtable
Final Roundtable in a series of online "RNAi Roundtables" entitled, "Patisiran & Revusiran for Treatment of Transthyretin (TTR)-Mediated Amyloidosis", consisting of presentations by Alnylam scientists, clinical collaborators and patient advocates review recent progress in many of the company's development-stage pipeline programs will be held on August 20 at 9 am. Webcast Link
05:48 EDTTSROMizuho keeps TESARO, Verastem, OncoMed as top biotech picks
Subscribe for More Information
August 19, 2015
07:22 EDTTSROCitigroup to hold a conference
Subscribe for More Information
August 17, 2015
06:22 EDTALNYPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
August 14, 2015
08:36 EDTALNYAlnylam Pharmaceuticals to hold a roundtable
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use